Acuta Capital Partners as of Sept. 30, 2020
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 43 positions in its portfolio as reported in the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Immunomedics | 11.8 | $44M | 512k | 85.03 | |
| Kura Oncology (KURA) | 8.1 | $30M | 973k | 30.64 | |
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 7.6 | $28M | 250k | 111.43 | |
| Celldex Therapeutics Com New (CLDX) | 6.2 | $23M | 1.5M | 14.83 | |
| Sage Therapeutics (SAGE) | 3.7 | $14M | 225k | 61.12 | |
| Compass Pathways Sponsored Ads (CMPS) | 3.7 | $14M | 390k | 34.90 | |
| Larimar Therapeutics (LRMR) | 3.4 | $13M | 830k | 15.17 | |
| Mersana Therapeutics (MRSN) | 3.4 | $12M | 668k | 18.62 | |
| Aldeyra Therapeutics (ALDX) | 3.3 | $12M | 1.6M | 7.41 | |
| Trillium Therapeutics Com New | 3.3 | $12M | 853k | 14.21 | |
| 89bio (ETNB) | 2.9 | $11M | 418k | 25.66 | |
| Relmada Therapeutics (RLMD) | 2.8 | $10M | 277k | 37.62 | |
| Iovance Biotherapeutics (IOVA) | 2.8 | $10M | 315k | 32.92 | |
| Altimmune Com New (ALT) | 2.5 | $9.1M | 688k | 13.20 | |
| Immunovant (IMVT) | 2.4 | $8.8M | 250k | 35.19 | |
| Cytokinetics Com New (CYTK) | 2.1 | $7.7M | 358k | 21.65 | |
| Rapt Therapeutics (RAPT) | 2.1 | $7.7M | 240k | 32.20 | |
| Lifesci Acquisition Corp Unit 03/31/2025 | 2.1 | $7.6M | 560k | 13.60 | |
| Surface Oncology | 2.0 | $7.5M | 1.1M | 6.90 | |
| Athira Pharma (ATHA) | 1.8 | $6.7M | 363k | 18.46 | |
| Avidity Biosciences Ord (RNA) | 1.8 | $6.6M | 235k | 28.15 | |
| Catalyst Biosciences Com New | 1.7 | $6.4M | 1.5M | 4.30 | |
| Selecta Biosciences | 1.6 | $5.9M | 2.4M | 2.48 | |
| Cymabay Therapeutics | 1.5 | $5.5M | 765k | 7.24 | |
| Apellis Pharmaceuticals (APLS) | 1.4 | $5.0M | 167k | 30.17 | |
| Iveric Bio | 1.2 | $4.5M | 803k | 5.64 | |
| Arrowhead Pharmaceuticals (ARWR) | 1.2 | $4.4M | 102k | 43.06 | |
| Cardiff Oncology (CRDF) | 1.2 | $4.3M | 306k | 14.19 | |
| Health Sciences Acq Corp 2 Ord Shs | 1.2 | $4.3M | 393k | 11.00 | |
| Avadel Pharmaceuticals Sponsored Adr | 1.0 | $3.6M | 705k | 5.04 | |
| Syndax Pharmaceuticals (SNDX) | 1.0 | $3.6M | 241k | 14.76 | |
| Panacea Acquisition Corp Unit 99/99/9999 | 0.9 | $3.4M | 280k | 12.00 | |
| Annexon (ANNX) | 0.9 | $3.3M | 110k | 30.23 | |
| Xenon Pharmaceuticals (XENE) | 0.9 | $3.3M | 300k | 11.07 | |
| Fulcrum Therapeutics (FULC) | 0.8 | $3.0M | 382k | 7.93 | |
| Concert Pharmaceuticals I equity | 0.8 | $2.9M | 300k | 9.82 | |
| Verastem | 0.8 | $2.9M | 2.4M | 1.21 | |
| BioCryst Pharmaceuticals (BCRX) | 0.6 | $2.3M | 660k | 3.43 | |
| Axsome Therapeutics (AXSM) | 0.4 | $1.6M | 23k | 71.24 | |
| Karuna Therapeutics Ord | 0.3 | $1.0M | 14k | 77.33 | |
| Unum Therapeutics Ord | 0.3 | $959k | 410k | 2.34 | |
| Clearside Biomedical (CLSD) | 0.3 | $947k | 615k | 1.54 | |
| Wave Life Sciences SHS (WVE) | 0.2 | $913k | 108k | 8.49 |
